Key Financial Figures - Standalone (₹ in Lakhs)
Income Statement Highlights:
- Revenue from Operations: FY26: ₹66,749.85; FY25: ₹50,249.34 (32.8% increase)
- Other Income: FY26: ₹840.44; FY25: ₹299.88
- Total Income: FY26: ₹67,590.29; FY25: ₹50,549.22
- Purchase of Stock-in-Trade: FY26: ₹65,599.01; FY25: ₹48,859.26
- Finance Costs: FY26: ₹2,529.74; FY25: ₹1,621.53 (56% increase)
- Profit Before Tax: FY26: ₹2,866.82; FY25: ₹1,880.61
- Net Profit: FY26: ₹2,198.16; FY25: ₹1,402.16
- EPS Basic: FY26: ₹0.91; FY25: ₹0.58
Balance Sheet Highlights (as of 31-Mar-2026):
- Total Assets: ₹59,417.97 lakhs (Previous: ₹40,322.66 lakhs)
- Inventory: ₹20,665.52 lakhs
- Trade Receivables: ₹19,922.85 lakhs
- Borrowings (Current): ₹25,069.68 lakhs
- Equity Share Capital: ₹2,406.59 lakhs (unchanged)
- Other Equity: ₹12,863.92 lakhs (Previous: ₹10,664.23 lakhs)
Key Financial Figures - Consolidated (₹ in Lakhs)
Income Statement Highlights:
- Revenue from Operations: Not separately stated in consolidated summary
- Profit Before Tax: FY26: ₹3,053.97; FY25: ₹2,001.67
- Net Profit Attributable to Owners: FY26: ₹2,330.33; FY25: ₹1,496.75
- EPS Basic: FY26: ₹0.97; FY25: ₹0.62
Balance Sheet Highlights (as of 31-Mar-2026):
- Total Assets: ₹64,174.91 lakhs (Previous: ₹40,626.91 lakhs)
- Inventory: ₹21,874.03 lakhs
- Trade Receivables: ₹23,334.01 lakhs
- Borrowings (Current): ₹25,510.51 lakhs
Legal Matter Disclosure
The company disclosed details of a litigation outcome against Regans International DMCC and Nand Biharilal Chhabaria Biharilal Chunilal. A Dubai court awarded the company AED 4,030,934.00 (approximately ₹9,18,82,890) plus 5% annual interest until full payment. As of 31st March 2026, the company had received ₹4,68,00,535 (including interest), with the balance expected to be received in the future.
Fundraising Activities
The Board approved raising funds up to ₹1,500 crores through Foreign Currency Convertible Bonds (FCCBs). Key milestones:
- EGM passed special resolution on 11th August 2025
- Received in-principle approval from BSE on 26th September 2025 for USD 35,000,000
- Obtained Loan Registration Number from RBI on 15th October 2025
- Surrendered initial LRN as fundraising didn't fructify
- Fresh RBI approval obtained on 25th March 2026 for new FCCB proposal
Acquisition Activity
The company entered into a definitive agreement on 4th August 2025 with Srigen Lifesciences Private Limited to acquire an operational API manufacturing facility in Telangana for ₹25,50,00,000. The acquisition includes land, building, and plant & machinery.
Accounting Policy Change
The company voluntarily adopted Indian Accounting Standards (Ind AS) from 1st April 2025, with transition date of 1st April 2024. The notes include a reconciliation from previous GAAP to Ind AS.
Subsidiaries Included in Consolidation
The consolidated results include the following subsidiaries:
- Sudarshan Pharma Lifescience Private Limited
- Lifescience Chemical Private Limited
- Ratna Lifesciences Private Limited
- Sudarshan Maven Pharma Private Limited
- Sudarshan Pharma Industries Private Limited, Singapore
- Ishwari Healthcare Private Limited
- Cibachem General Trading LLC, Dubai
- Sudarshan Pharma Poland Limited Liability Company, Poland (from 17th December 2025)